Overview

A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Melli

Status:
NOT_YET_RECRUITING

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate how fasting and stopping the use of tirzepatide affects the amount of food and drink that stays in the stomach after a meal. Ultrasound will be used to check the stomach content after a test meal.

Phase:

PHASE1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Tirzepatide